新規抗精神病薬アリピプラゾールの処方動向 : 市販開始後3カ月間における処方の12週間追跡調査

概要

論文の詳細を見る
Aripiprazole, an antipsychotic having a novel dopamine D_2 partial agonist mechanism of action was launched in Japan in June 2006. Since there is still not much experience of using this new drug in Japan, we decided to find out how doctors prescribe it and whether its prescription has been affecting chlorpromazine (CP) equivalent dosages of antipsychotics and concomitant use of anticholinergics by examining antipsychotic and anticholinergic prescriptions over 12 weeks for patients who were started on aripiprazole within 3 months of approval. We also sent a questionnaire to prescribers concerning their expectations of aripiprazole and the reasons if it had been discontinued. It was found that aripiprazole was much prescribed to patients receiving a single antipsychotic medication, and the most common expectation was further improvement of hallucinations and delusions. After the 12 weeks of the follow up, the prescription of aripiprazole increased the number of antipsychotics significantly but did not affect the CP equivalent dosage and percentage of concomitantly used anticholinergics. We found that the most common reason for discontinuation of aripiprazole was insufficient effectiveness for hallucinations and delusions, but in no patient was it withdrawn due to adverse effects. It seems that a complete switch to aripiprazole takes time even though it was prescribed to patients for whom switching was relatively easy, raising the possibility of polypharmacy and prolonged administration of anticholinergics. It is thus necessary to continuously monitor the administration of aripiprazole as well as that of other antipsychotics in order to prevent polypharmacy.
日本医療薬学会の論文
2007-09-10

新規抗精神病薬アリピプラゾールの処方動向 : 市販開始後3カ月間における処方の12週間追跡調査

スポンサーリンク

概要

著者

関連論文

スポンサーリンク